Health Care Supplies
featured
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
» Read MoreMore
-
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
-
Johnson & Johnson's stock has gained 22 percent on the year and trades at a higher P/E ratio than its competitors. It is not a good buy now, but a great hold, TheStreet.com says.
-
The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.
-
The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.
-
Roger Parloff, Fortune senior editor, says businesses are sprouting in states like Colorado and Washington, where selling cannabis is now legal.
-
If you smoke, you might have to pay thousands extra for employee-based health insurance under Obamacare starting next year.
-
*To add 2 cents to 3 cents to 2013 EPS, at least 18 cents in FY14. Feb 14- U.S. drug wholesaler Cardinal Health Inc said it plans to acquire AssuraMed, a privately held direct-to-home medical supply distributor, for about $2.07 billion.
-
*Fiscal 2013 forecast tightened to $3.42- $3.50 a share. Net earnings in the second quarter ended Dec. 31 rose to $303 million, or 88 cents a share, from $262 million, or 75 cents a share, a year earlier, the company said on Tuesday.
-
*Fiscal 2013 forecast tightened to $3.42- $3.50 a share. Net earnings in the second quarter ended Dec. 31 rose to $303 million, or 88 cents a share, from $262 million, or 75 cents a share, a year earlier, the company said on Tuesday.
-
On a First on CNBC interview, Cochlear CEO Chris Roberts tells CashFlow about his company's products and plans for global expansion.
-
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
-
Pfizer's unit Zoetis plans to sell 86.1 million shares at between $22 and $25 each in an initial public offering.
-
One of the worst flu seasons in a decade is putting further strains on an already sluggish U.S. economy as companies get slammed with increased health care costs and lower productivity from widespread worker absences.
-
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.